한빛사 논문
Wooram Parka,*, Kwang Hoon Songb,*, Jaesung Limc, Chun Gwon Parkc, Junsang Dohd and Dong Keun Hane
aDepartment of Biomedical-Chemical Engineering, The Catholic University of Korea, Bucheon, Republic of Korea; bDepartment of Nano-Bioengineering, Incheon National University, Incheon, Republic of Korea; cDepartment of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Suwon, Republic of Korea; dDepartment of Materials Science and Engineering, Research Institute of Advanced Materials (RIAM), Institute of Engineering Research, Seoul National University, Seoul, Republic of Korea; eDepartment of Biomedical Science, CHA University, Seongnam, Republic of Korea
CONTACT to Junsang Doh
Department of Materials Science and Engineering, Research Institute of Advanced Materials (RIAM),
Institute of Engineering Research, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea;
Dong Keun Han
Department of Biomedical Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea
*These authors contributed equally to the work.
Abstract
Cancer immunotherapy has been extremely successful in curing patients over the last decade. Immune checkpoint blockades (ICBs) that unleash the brakes in T-cells to promote cytotoxicity against cancer cells are the most successful forms of cancer immunotherapy, yet therapeutic efficacy needs to be improved as only a fraction of patients responds. Dendritic cells (DCs) are immune cells that prime immune responses by collecting information in tumour tissues, and carrying that information to T-cells, thus delivering proper information to DCs is essential. Biomaterial-based approaches can be powerful tools for this purpose, as biomaterials allow us to deliver a variety of immunotherapeutic agents at the right time and place. Herein, we review the key concepts of cancer immunotherapy; discuss the principles for designing biomaterials to deliver immunomodulatory molecules; and outline biomaterial-based strategies to prime anti-cancer immune responses. Specifically, we focus on two widely used forms of biomaterials, multifunctional nanoparticles and biocompatible scaffolds.
논문정보
관련 링크
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기